<DOC>
	<DOCNO>NCT02477865</DOCNO>
	<brief_summary>This phase III , multicenter , randomize , double-blind , placebo-controlled study plan include approximately 387 T2DM patient receive least 8 week treatment diet control exercise； receive glucose-lowering agent within 8 week prior screen ; inadequately control blood glucose.The subject would receive PEX168 placebo monotherapy 52weeks total .</brief_summary>
	<brief_title>Efficacy Safety Study PEX168 Monotherapy Diabetes Mellitus Type 2 Patients</brief_title>
	<detailed_description>This study consist 4 periods： Period 1：Up 3 week screen period . Period 2：A 4-week PEX168 dummy run-in period . Period 3：A 52-week treatment period ( include 24-week core treatment period 28-week extended treatment period ) . Period 4 : A 4-week safety follow-up period . This study last approximately 63 week , include approximately 60 clinic visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion Criteria ( 8 must meet ) ： 1 . Type 2 diabetes mellitus confirm 1999 WHO criteria； 2 . Men women； 3 . Age sign ICF≥18 year ≤78 years； 4 . Body mass index ( BMI ) 2040 Kg/m2； 5 . At least 8 week treatment diet control exercise receive prior screening； 6 . No glucoselowering agent receive within 8 week prior screening； 7 . 7.5 % ≤HbA1c≤11.0 % screening（local centralize test）； 7.0 % ≤HbA1c≤10.5 % randomization（centralized test），and FBG &lt; 13.9 mmol/L（local test）； 8 . Ability understand procedure approach study , willingness complete study strict compliance protocol voluntarily sign ICF . Exclusion criteria： 1 . Investigator suspect subject allergy study drug； 2 . Use following medication therapy prior screening： 1 . GLP1 receptor agonist , GLP1 analogues , DPP4 inhibitor incretin analogue . 2 . Growth hormone therapy within 6 month prior screening； 3 . History drug abuse alcohol abuse； 4 . Participation clinical trial within 3 month prior screening； 5 . Prolonged intravenous , oral intraarticular treatment corticosteroid within 2 month prior screen ; 6 . Use weight control agent surgery within 2 month prior screen ; 7 . Any medication use prior screen investigator 's discretion may confound interpretation efficacy safety data； 3 . History evidence follow condition prior screening： 1 . Type 1 diabetes mellitus , single gene mutation DM , DM associate pancreatic injury，or secondary DM； 2 . History hypertension SBP＞160 mmHg and/or DBP＞100 mmHg； 3 . History acute/chronic pancreatitis , history symptomatic cholecystopathy ; 4 . History myeloid Ccell carcinoma , history multiple endocrine neoplasm （MEN） 2A 2B syndrome , relate familiar history； 5 . Gastric empty disorder , severe chronic gastrointestinal disorder ; 6 . History severe hypoglycemia , unconsciousness severe hypoglycemia history； 7 . Significant hematological disorder , diseases； 8 . Severe diabetic complication opinion investigator make subject suitable participate study； 9 . Tumors organ system treat within 5 year prior screening； 10 . Coronary angioplasty , coronary stenting , coronary artery bypass , uncompensated heart failure （NYHA Class III IV） , within 6 month prior screening； 11 . Acute metabolic complication within 6 month prior screening； 12 . Thyroid dysfunction within 6 month prior screening； 13 . Blood lipid disorder within 6 month prior screening； 14 . Any severe trauma severe infection within 1 month prior screening； 4 . Laboratory indicator meet follow criterion prior screening： 1 . ALT＞2.5×ULN and/or AST＞2.5×ULN and/or total bilirubin＞2.5×ULN； 2 . Hemoglobin≤100 g/L； 3 . Serum creatinine＞1.5×UNL eGFR &lt; 45 ml/min/1.73 m2； eGFR calculate as：186.3 × [ （Serum Creatinine（mmol/L）/88.4） ] −1.154 × [ Age ( year ) ] − 0.203 × 1.223 × 0.742 （Females） ×1（Males） 4 . Serum thyroidstimulating hormone（TSH） reference range assess clinically significant investigator ; 5 . Fasting TGL＞5.64 mmol/L（500 mg/dl）； 6 . Blood amylase urine amylase &gt; ULN assess clinically significant investigator； 7 . Any clinically significant laboratory abnormalities； 5 . Clinically significant 12lead ECG abnormalities； 6 . Blood donation loss≥400 mL，or receipt blood donation within 4 week prior screening； 7 . Pregnant lactate woman , men woman childbearing potential willing take contraceptive measure study； 8 . Any condition subject investigator 's discretion may compound interpretation efficacy safety data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>